Primary immunodeficiencies: HSCT experiences of a single center in Turkey.
allogeneic stem cell transplantation
bone marrow transplantation
hematopoietic stem cell transplantation
pediatric transplantation
primary immunodeficiency
Journal
Pediatric transplantation
ISSN: 1399-3046
Titre abrégé: Pediatr Transplant
Pays: Denmark
ID NLM: 9802574
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
revised:
28
04
2020
received:
06
09
2019
accepted:
19
03
2021
pubmed:
7
6
2021
medline:
3
2
2022
entrez:
6
6
2021
Statut:
ppublish
Résumé
Primary immunodeficiency diseases (PID) are characterized by the occurrence of frequent infections and are caused by many genetic defects. Hematopoietic stem cell transplantation (HSCT) is the only curative treatment option for the majority of PID. As a Pediatric Hematology-Oncology-Immunology Transplantation Unit, we wanted to present our HSCT experience regarding treatment of primary immunodeficiency diseases. 58 patients were included in the study between January 2014 and June 2019. We searched 9/10 or 10/10 matched-related donor (MRD) firstly, in the absence of fully matched-related donor. We screened matched unrelated donor (MUD) from donor banks. MRD was used in 24 (41.3%) patients, MUD in 20 (34.4%) patients, and haploidentical donors in 14 (24.1%) patients. Demographic data, HSCT characteristics, and outcome were evaluated. While 16 patients had severe combined immunodeficiency (SCID), the remaining was non-SCID. Of the 58 patients, 38 were male and 20 were female. Median age at transplantation was 12 months (range: 2.5-172 months). Combined immunodeficiencies consisted 67.2% of patients. Mean follow-up time was 27 months (6 months-5 years). Median neutrophil, lymphocyte, and thrombocyte engraftment days were similar in comparison of both donor type and stem cell source. The most common complication was acute GvHD in 15 (25.8%) patients. In total, five patients (31%) belonging to the SCID group and 10 patients (23.8%) belonging to the non-SCID group died. Our total mortality rate was 15 (25.8%) in all patients. We would like to present our HSCT experiences as a pediatric immunology transplantation center. Existing severe infections before transplantation period, BCGitis, and CMV are important issues of transplantation in Turkey. However, the follow-up time is shorter than some studies, our results regarding complications and survival are similar to previous reports.
Sections du résumé
BACKGROUND
BACKGROUND
Primary immunodeficiency diseases (PID) are characterized by the occurrence of frequent infections and are caused by many genetic defects. Hematopoietic stem cell transplantation (HSCT) is the only curative treatment option for the majority of PID. As a Pediatric Hematology-Oncology-Immunology Transplantation Unit, we wanted to present our HSCT experience regarding treatment of primary immunodeficiency diseases.
METHODS
METHODS
58 patients were included in the study between January 2014 and June 2019. We searched 9/10 or 10/10 matched-related donor (MRD) firstly, in the absence of fully matched-related donor. We screened matched unrelated donor (MUD) from donor banks. MRD was used in 24 (41.3%) patients, MUD in 20 (34.4%) patients, and haploidentical donors in 14 (24.1%) patients. Demographic data, HSCT characteristics, and outcome were evaluated. While 16 patients had severe combined immunodeficiency (SCID), the remaining was non-SCID.
RESULTS
RESULTS
Of the 58 patients, 38 were male and 20 were female. Median age at transplantation was 12 months (range: 2.5-172 months). Combined immunodeficiencies consisted 67.2% of patients. Mean follow-up time was 27 months (6 months-5 years). Median neutrophil, lymphocyte, and thrombocyte engraftment days were similar in comparison of both donor type and stem cell source. The most common complication was acute GvHD in 15 (25.8%) patients. In total, five patients (31%) belonging to the SCID group and 10 patients (23.8%) belonging to the non-SCID group died. Our total mortality rate was 15 (25.8%) in all patients.
CONCLUSIONS
CONCLUSIONS
We would like to present our HSCT experiences as a pediatric immunology transplantation center. Existing severe infections before transplantation period, BCGitis, and CMV are important issues of transplantation in Turkey. However, the follow-up time is shorter than some studies, our results regarding complications and survival are similar to previous reports.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14063Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Bousfiha A, Jeddane L, Picard C, et al. The 2017 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2018;38(1):129-143.
Gennery AR, Slatter MA, Grandin L, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol. 2010;126:602-610.
de la Morena MT, Nelson RP Jr. Recent advances i transplantation for primary immune Immunodeficiency diseases: a comprehensive review. Clin Rev Allergy Immunol. 2014;46(2):131-144.
Griffith LM, Cowan MJ, Notarangelo LD, et al. Primary immune DeficienCyC treatment consortium (PIDTC) report. J Allergy Clin Immunol. 2014;133(2):335-347.
Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. J Clin Immunol. 2018;38(1):96-128.
Buckley RH, Schiff SE, Schiff RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined Immunodeficiency. N Engl J Med. 1999;340(7):508-516.
Pai S-Y, Logan BR, Griffith LM, et al. Transplantation outcomes for severe combined Immunodeficiency, 2000-2009. N Engl J Med. 2014;371:434-446.
Ikinciogullari A, Cagdas D, Dogu F, et al. Tezcan I;Turkish Pediatric Bone Marrow Transplantation Sub Group (TPBMT-SG). Clinical Features and HSCT Outcome for SCID in Turkey. J Clin Immunol. 2019;39(3):316-323.
Laberko A. Gennery AR Clinicalconsiderations in the hematopoietic stem cell transplant management of primary immunodeficiencies. Expert Rev Clin Immunol. 2018;14(4):297-306.
Passweg JR, Baldomero H, Bader P, et al. Use of haploidentical stem cell transplantation continues to increase: the 201 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2017;52(6):811-817.
Balashov D, Shcherbina A, Maschan M, et al. Single-center experience of unrelated and haploidentical stem cell transplantation with TCRαβ and CD19 depletion in children with primary immunodeficiency syndromes. Biol Blood Marrow Transplant. 2015;21(11):1955-1962.
Neven B, Diana JS, Castelle M, et al. Haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for primary immunodeficiencies and inherited disorders in children. Biol Blood Marrow Transplant. 2019;25(7):1363-1373.
Cavazzana M, Touzot F, Moshous D, Neven B, Blanche S, Fischer A. Stem cell transplantation for primary immunodeficiencies: the European experience. Curr Opin Allergy Clin Immunol. 2014;14(6):516-520.
Sanal O, Tezcan I. Thirty years of primary immunodeficiencies in Turkey. In The year in human and medical genetics: inborn errors of immunity I. Casanova Jean-Laurent, Conley Mary Ellen, Notarangelo Luigi, eds. Ann N Y Acad Sci. 2011;1238:15-23.
DiNardo L, Brown V, Perez E, Bunin N, Sullivan KE. A singlecenter study of hematopoietic stem cell transplantation for primary immune deficiencies (PIDD). Pediatr Transplant. 2012;16:63-72.
Patiroglu T, Akar HH, Unal E, Ozdemir MA, Karakukcu M. Hematopoietic stem cell transplant for primary immunodeficiency diseases: a single-center experience. Exp Clin Transplant. 2017;15(3):337-343.
Yıldıran A, Çeliksoy MH, Borte S, et al. Hematopoietic stem cell transplantation in primary immunodeficiency patients in the black sea region of Turkey. Turk J Haematol. 2017;1;34(4):345-349.
Barkai G, Somech R, Stauber T, Barziali A, Greenberger S. Bacille Calmette-Guerin (BCG) complications in children with severe combined immunodeficienCyC (SCID). Infect Dis (Lond). 2019;51(8):585-592.
Yeganeh M, HeidarzadeM PZ, Parvaneh N, et al. Severe combined immunodeficienCyC: a cohort of 40 patients. Pediatr Allergy Immunol. 2008;19:303-306.
Freeman AF. Hematopoietic Stem Cell Transplantation in Primary Immunodeficiencies Beyond Severe Combined Immunodeficiency. J Pediatric Infect Dis Soc. 2018;7(suppl_2):S79-S82.
Lunde LE, Dasaraju S, Cao Q, et al. Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival. Bone Marrow Transplant. 2015;50(11):1432-1437.
Sun YQ, Wang Y, Zhang XH, et al. AVirus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation. Ann Hematol. 2019;98(8):1877-1883.